誉衡药业10月23日获融资买入1450.04万元，融资余额3.80亿元

Core Insights - On October 23, Yuheng Pharmaceutical experienced a decline of 1.53% with a trading volume of 137 million yuan, indicating a negative market sentiment towards the company [1] - The company reported a financing net buy of -3.40 million yuan on the same day, suggesting a higher level of selling pressure compared to buying [1] - As of October 23, the total margin balance for Yuheng Pharmaceutical stood at 380 million yuan, which is 5.37% of its circulating market value, indicating a relatively high leverage position [1] Financing and Margin Data - On October 23, the financing buy amount was 14.50 million yuan, while the financing repayment was 17.90 million yuan, leading to a net financing outflow [1] - The current financing balance of 380 million yuan exceeds the 70th percentile level over the past year, indicating a significant level of borrowing [1] - In terms of securities lending, there were no shares sold on October 23, with a total of 0 shares in the lending balance, which is at the 80th percentile level over the past year [1] Company Financial Performance - As of September 19, the number of shareholders for Yuheng Pharmaceutical was 105,700, a decrease of 1.03% from the previous period, while the average circulating shares per person increased by 1.04% to 19,831 shares [2] - For the first half of 2025, the company reported a revenue of 1.10 billion yuan, a year-on-year decrease of 9.97%, while the net profit attributable to shareholders was 134 million yuan, reflecting a year-on-year increase of 7.56% [2] Dividend and Shareholding Information - Since its A-share listing, Yuheng Pharmaceutical has distributed a total of 692 million yuan in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 31.23 million shares as a new shareholder [3]